secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001493152-23-016286
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon Q1 net loss narrows to $5.6M; cash runway into 2025; PLACCINE IND planned Q4 2023
--------------------------------------------------------------------------------

- Net loss of $5.6M ($0.68/share) vs $10.5M ($1.82/share) in Q1 2022; operating expenses down 5% to $5.7M.
- Cash and equivalents $37.3M at March 31, 2023; expects funding operations into 2025, plus $1.9M in NJ NOL sales.
- Phase 1/2 trial of IMNN-001 + Avastin in advanced ovarian cancer opened for enrollment at MD Anderson and others.
- Pre-IND consultation filed with FDA for PLACCINE COVID-19 booster; IND expected Q4 2023.
- Collaborated with Wistar Institute to develop PLACCINE vaccines for infectious diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315223016286/0001493152-23-016286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315223016286/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-016286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer